GLP-1 consumers have a latest symptom to watch for: Sudden vision loss in one eye.

The Food and Drug Administration (FDA) declared on November 9 that it will require drugmakers to add information to the warning labels of Ozempic, Wegovy, Mounjaro, Zepbound and other GLP-1 medications about “a potential increased risk” of a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION).GLP-1 medications are approved to treat type 2 diabetes and to help people lose weight and keep it off.NAION joins a growing list of side effects linked to GLP-1s, adding a second eye warning to several labels.The U.S. labels for Ozempic, Rybelsus, Trulicity, Mounjaro, and Zepbound already warn about diabetic retinopathy, a diabetes-related eye disease, according to each drug’s prescribing information.The two conditions affect different parts of the eye. Diabetic retinopathy damages tiny blood vessels in the retina, the layer at the back of the eye that senses light, according to the National Eye Institute. NAION damages the optic nerve when it doesn’t get enough blood, according to the FDA’s announcement.Mihail Zilbermint, MD, director of endocrine hospitalists at Johns Hopkins, told Healthline he hasn’t seen NAION in his patients. He has seen vision worsen in some people after they start a GLP-1.“But we believe that’s probably related to rapid improvement in their sugar control, which can also be seen in someone who is starting insulin,” Zilbermint said.

A 2024 study published in JAMA Ophthalmology “initially triggered” the FDA’s review, the agency told Healthline.

According to recent reports, the study found a higher risk of NAION in people prescribed semaglutide, the active ingredient in Ozempic and Wegovy, than in people prescribed other diabetes or weight-loss drugs.The authors wrote that more research is needed to determine whether semaglutide causes NAION.Joseph F. Rizzo III, MD, director of the Neuro-Ophthalmology Service at Mass Eye and Ear in Boston, served as the study’s corresponding author.

In a recent development, in a 2024 podcast, Rizzo noted he and a resident saw three patients with NAION who were taking semaglutide for about a week.“And because NAION is a fairly uncommon disorder in the general population, the fact that we had three within a relatively short period of time led me to suspect that there was a higher risk of developing NAION in patients on semaglutide,” Rizzo said. The FDA analyzed clinical trials for multiple GLP-1 drugs and noted that NAION cases were reported with every GLP-1 on the market, according to its announcement. Those findings led the FDA to require the warning for the entire drug class, the agency told Healthline.

About 70% to 80% of people with NAION first notice vision loss when they wake up, according to StatPearls. The FDA listed these symptoms:.

No treatment has been proven to reverse vision loss from NAION, according to StatPearls.

“Patients experiencing sudden, painless vision loss in one eye should contact their healthcare professional immediately and should not stop their medication without consulting their provider first,” the FDA told Healthline.

In the announcement, the agency told doctors to promptly refer patients with suspected NAION to an ophthalmologist.

The FDA listed these possible risk factors for NAION:.

The FDA told Healthline that many people who take GLP-1s also have these conditions, which made reports of NAION in GLP-1 people “challenging” to interpret.

Industry observers note that across 126 clinical trials, the FDA found about 6 NAION cases per 100,000 people taking a GLP-1 for a year, and about 4 per 100,000 people taking a placebo or another diabetes drug for a year.In real-world data, NAION was more common with GLP-1s than with one type of diabetes pill, but the FDA found no significant increase compared with another type, the agency told Healthline.Zilbermint remarked patients who saw the news have worried about losing their vision. He tells them that “many of the serious harms, including the potential harm of NAION, are rare.”“The overall risk is still very small,” he said.

Regulators in other countries have added NAION warnings, mostly for semaglutide:.

The FDA told Healthline the benefits of GLP-1s “continue to outweigh their risks when used as directed.”The FDA has also approved some GLP-1s to lower the risk of heart attack and stroke, reduce the risk of worsening kidney disease, and treat sleep apnea and a type of liver disease.Zilbermint stated that “for most of my patients with obesity, diabetes and heart disease, the benefits clearly outweigh the risks.”“But we definitely have to decide patient by patient,” he added.

The labeling change applies to these medications, according to the FDA’s announcement:.

As of publication, the FDA’s online label database did not yet show the new warning on the drugs’ labels.

→ Read original article